Asociación de Economía de la Salud, La economía de la salud en la reforma del sector: quintas jornadas internacionales de economía de la salud. Buenos Aires, 1996.

Bennett S, Ngalande-Banda E, Public and private rotes in health: a review and analysis of experience in Sub-Saharan Africa. World Health Organization, Division of Strengthening of Health Services, Geneva, 1994.

Chaulagai CN. Community financing for essential drugs in Nepal. World Health Forum 1995; 16:92-94.

Cetley A. From policy to practice: the future of the Bangladesh National Drug Policy. Penang, Malaysia: International Organization of Consumers Unions (IOCU), 1992.

Centre International de l’Enfance, CF, UNICEF, OMS. Argent et santé: expériences de financement communautaire en Afrique. Actes du séminaire international, Paris, France, 24-27 September 1991.

De Joncheere K. Puede Centroamérica pagar sus medicamentos? National University, Organización Panamerica de la Salud/Organización Mundial de la Salud. San José, Costa Rica, Noviembre, 1994.

Dujardin B. Book review of Implementing the Bamako Initiative in Africa by B. Mc Pake, K. Hanson, A. Mills. Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Publication No. 8, 1992.

Dumoulin J, Kaddar M, Velasquez G. Accès aux médicaments et financement: analyse économique et financière de base. Geneva: WHO; 1991. (WHO/DAP/91.5).

Drummond M, Teeling Smith G, Wells N, Economic evaluation in the development of medicines. Office of Health Economics, London, 1988.

Gilson L, Mills A. Health sector reforms in Sub-Saharan Africa: lessons of the past 10 years. In: Berman P. ed. Health sector reform in developing countries: making health development sustainable by P. Berman, Ed. Harvard Series on Population and International Health, Harvard University Press, Boston, 1995.

Gonzalez García G, Remedios políticos para los medicamentos. Isalud Publications, Buenos Aires, 1994.

Graham D. The Australian pharmaceutical benefits scheme. Australian Prescriber 1995; 18:2.

Haaijer-Ruskamp FM, Dukes MNG. Drugs and money: the problem of cost containment. WHO Collaborating Centre for Clinical Pharmacology and Drug Policy Science and Pharmaceutical Unit, Styx Publications, Groningen, The Netherlands, 1991.

Huttin C. Le médicament: contraintes et enjeux d’un marché. La Documentation Française, Paris, 1989.

Lobo F. Medicamentos: política y economía. Masson, S.A., Barcelona, 1992.

Lobo F, Velasquez G. Medicines and the new economic environment. Madrid, 1997 (to be published)

McPake B, Hanson K, Mills A. Experience to date of implementing the Bamako Initiative: a review and five country case studies. Health Economics and Financing Programme, Health Policy Unit, Department of Public Health and Policy, London School of hygiene and Tropical Medicine, 1991.

Molina Salazar R. Estructura de mercado y precios: el caso de los medicamentos esenciales. In: La industria y las finanzas en el Mexico actual. Universidad Autonoma Metropolitana, Mexico, 1995.

Molina Salazar R. Inovación y patentes en la industria farmacéutica. In: mercados y regulación. Universidad Autonoma Metropolitana, Mexico, 1993.

Molina Salazar R. Rivas Vilchis JF. Medicamentos, economía y salud: aspectos económicos y utilización medico-social de los medicamentos. Universidad Autonoma Metropolitana, Mexico, 1992.

Möller H, Pharasi B, Summers RS. Evaluation of pharmaceutical services in the Northern Transvaal Province. School of pharmacy, MEDICOS Pharmacy Project and Centre for Health Policy, University of the Witwatersrand, South Africa, 1994.

Mossialos E, Ranos C, Abel-Smith B. et al. Cost containment, pricing and financing of pharmaceuticals in the European Community: the policy-makers’ view. LSE Health and Pharmetrica S.A., Athens, Greece, 1994.

Nordic Council on Medicines, Health economics and medicines, Nordic Workshop on Health Economics. NLN Publication No. 31, Uppsala, Sweden, 1992.

Nordic Council on Medicines, Health economic evaluation of medicines. Nordic Workshop. NLN Publication No. 38, Uppsala, Sweden, 1995.

Quick JD, Rankin J, Laing RO, et al. Managing drug supply. Management Sciences for health in collaboration with World Health Organization, Action Programme on Essential Drugs, Kumarian Press, Hartford, USA, 1997.

Rankin J. Engaging the private sector in the public pharmaceutical system. International Conference on National medicinal drug policies, Sydney, 8-11 October 1995.

Rational Pharmaceutical Management Project (RPM) & Latin America and Caribbean Health and Nutrition Sustainability Project. Rapid pharmaceutical management assessment: an indicator-based approach. USA, July 1995.

Reddy S, Vandemoortele J. User financing of basic social services: a review of theoretical arguments and empirical evidence. Office of Evaluation, Policy and Planning, UNICEF, New-York, 1996.

Redwood H. Price regulation and pharmaceutical research: the limits of co-existence. Oldwicks Press Limited, Felistow, Suffolk, UK, 1993.

Redwood H. Public policy trends in drug pricing and reimbursement in the European Community. PharmacoEconomics, 1994;6:3-10.

Reekie W.D., Medicine prices and innovations: an international survey. IEA Health and Welfare Unit, London, 1996.

ReMed, Contribution á l’étude du recouvrement des coûts des médicaments dans le cadre d’une politique de santé dans les pays en développement. Réseau A Médicaments et Développement@, Paris, 1992.

Sacristan JA, Soto J. Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. The Annuals of Pharmacotherapy, 1993; 27:1126-1131.

Zerda Sarmiento A., Alternative drug pricing policies in the Americas. Geneva: WHO; 1995. (Health economics and drugs series 1; WHO/DAP/95.6).

Saxenian H. Getting the most out of pharmaceutical expenditures. Human Resources Development and Operations Policy, September 1994.

Velasquez, G. Médicaments et financement des systèmes de santé dans les pays du Tiers-Monde: le recouvrement des coûts, un concept à revoir. Revue Tiers-Monde, 1989, T. XXX, No. 118.

Waty MO. Analyse du système de recouvrement des coûts, Programme National PEV/SSP/ME-République de Guinée. Rapport d’une mission OMS/PAME, Genève, mars 1989.

Wertheimer Al, Grumer SK. Overview of international pharmacy pricing. Pharmaco-Economics, 1992;2:449-455.

World Health Organization, Action Programme on Essential Drugs. Financing essential drugs: report of a workshop. Harare, Zimbabwe: WHO; 1988.

World Health Organization, Action Programme on Essential Drugs. Global comparative pharmaceutical expenditures. Geneva: WHO; 1997 (Health economics and drugs series 3).

World Health Organization, Action Programme on Essential Drugs. Health reform and drug financing: overview of experiences, options and priorities for action. Geneva: WHO; 1997. (theme paper for discussion, DAP/MAC (9)/97.7).

World Health Organisation, Action Programme on Essential Drugs. Informal consultation on evolving public-private roles in the pharmaceutical sector. Geneva: WHO; 1996.

World Health Organisation, Action Programme on Essential Drugs. Latin American conference on economic and financial aspects of essential drugs Caracas. Geneva: WHO; 1992. (WHO/DAP/92.8 report).

World Health Organization Regional Office for Europe, Programme for pharmaceuticals in CCEE/NIS. Drug pricing systems in Europe: an overview. Copenhagen: WHO/EURO; 1994.

Zepeda Bermudez JA. Indùstria farmacêutica, estado e sociedade: crítica da polìtica de medicamentos no Brasil, Editora Hucitec sociedade brasileira de vigilância de medicamentos, São Paulo; 1995.